CN102370964A - Application of interleukin receptor antagonist protein to preparation of external use skin preparation - Google Patents
Application of interleukin receptor antagonist protein to preparation of external use skin preparation Download PDFInfo
- Publication number
- CN102370964A CN102370964A CN2010102547819A CN201010254781A CN102370964A CN 102370964 A CN102370964 A CN 102370964A CN 2010102547819 A CN2010102547819 A CN 2010102547819A CN 201010254781 A CN201010254781 A CN 201010254781A CN 102370964 A CN102370964 A CN 102370964A
- Authority
- CN
- China
- Prior art keywords
- preparation
- receptor antagonist
- interleukin
- antagonist protein
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of interleukin receptor antagonist protein to the preparation of an external use skin preparation. The interleukin receptor antagonist protein (ILRa) is prepared into the external use skin preparation such as cosmetics and the like which can be used on local parts of the skin, and the goals of beautification, skin tendering and skin disease treatment such as antianaphylaxis, red fading, antiphlogosis, telangiectasia eliminating and the like are reached.
Description
Technical field
The present invention relates to the application of interleukin-1 receptor antagonist protein in the preparation preparation for external application to skin.
Background technology
The interleukin-1 receptor antagonist protein is a kind of protein-based cytokine receptor antagonist that is present in human body, through the bind interleukin receptor, seals the activity of interleukin specifically.The interleukin-1 receptor antagonist protein of technique for gene engineering body outer clone production at present is mainly used in treatment of rheumatoid arthritis as a kind of injection medicine.Also do not see at present about the interleukin-1 receptor antagonist protein is made into preparation for external application to skin, be used for the report of sick treatment such as beautifying skin and skin allergy.
Summary of the invention
The object of the present invention is to provide the application of interleukin-1 receptor antagonist protein in the preparation preparation for external application to skin.
Among the present invention, the interleukin-1 receptor antagonist protein can be processed different dosage forms with substrates with different respectively.As being prepared into aqueous gels with gel-type vehicle; Perhaps be prepared into Emulsion, or be mixed with into aqueous solution with water with emulsion bases.
As one embodiment of the present invention:, process the interleukin-1 receptor antagonist protein external preparation that can directly be applied in skin with gel-type vehicle, aqueous solution or the emulsion bases mix homogeneously of interleukin-1 receptor antagonist protein and external preparation for skin.
As another embodiment of the invention: after the interleukin-1 receptor antagonist protein is made into liposome earlier, mix with gel-type vehicle, water or emulsion bases again, process the product that can be applied in skin.
As a kind of preferred implementation of the present invention: the interleukin-1 receptor antagonist protein is made into lyophilized powder earlier and preserves; Mix with the external-use gel that has prepared or aqueous solution or emulsion bases again before the use; Can keep the BA of interleukin-1 receptor antagonist protein and the effectiveness of external preparation for skin to greatest extent like this.
The content of interleukin-1 receptor antagonist protein in the external preparation described in the present invention is 10～500 mcg/ml (micrograms/gram).
Interleukin-1 receptor antagonist protein described in the present invention includes but not limited to recombination human leukopenic-1 receptor antagonist protein or its modified protein.
Gel-type vehicle of the present invention is the aqueous gel substrate that contains water solublity wetting agent, hydrophilic gel and PH regulator.Described water solublity wetting agent can be selected from one or more the mixing in glycerol, propylene glycol, hyaluronic acid, heparin and the aminoacid etc.Described hydrophilic gel can be selected from one or more the mixing in carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, silicone natural gum, alginic acid and the sodium salt thereof etc.
The present invention has the following advantages:
(1) interleukin-1 receptor antagonist protein (ILRa) is prepared into preparation for external application to skin such as cosmetics and can uses being used for local skin, reaches antiallergic, takes off red, antiinflammatory, the purpose of treating skin disease such as Red blood streak dispelling and facial beautification and skin rejuvenation function.
(2) the present invention can keep and keep the maximum BA of interleukin-1 receptor antagonist protein; Make it infiltrate its inherent biological effect of skin performance; But also have advantages of good skin sensation and hold and stay characteristic, and good wettability, permeability and absorbability.
(3) the present invention is made into the lyophilized powder preservation earlier with the interleukin-1 receptor antagonist protein; Mix with the external-use gel that has prepared or aqueous solution or emulsion bases again before the use; Can keep the BA of interleukin-1 receptor antagonist protein and the effectiveness of external preparation for skin to greatest extent like this.
The specific embodiment
Below in conjunction with experimental example and embodiment the present invention is set forth, yet protection scope of the present invention is not only to be confined to following examples.The those of ordinary skill of affiliated technical field all can be realized the object of the invention according to content disclosed by the invention.
Interleukin-1 receptor antagonist protein described in following examples can adopt and include but not limited to recombination human leukopenic-1 receptor antagonist protein or its modified protein.
Embodiment 1: contain the aqueous gel and the preparation thereof of interleukin-1 receptor antagonist protein
Use conventional hybrid technology to mix following (A) aqueous gel substrate and (B) contain the interleukin-1 receptor antagonist protein
Glycerol, pyrrolidone sodium carboxylate, hyaluronic acid, acrylic ester/C10-30 alkyl acrylate cross-linked polymer, allantoin, phenoxyethanol is dissolved in the water and fully mixes in 55 ℃ obtain raw material A; Be cooled to 40 ℃; Add the interleukin-1 receptor antagonist protein and, transfer PH to 6.8 to get final product with lactic acid or the triethanolamine of 0.1M then with the further stirring and evenly mixing of agitator.It is little that the aqueous gel that so makes has viscosity, is used in skin surface and has the advantages of good skin sensation, and fabulous wettability and permeability are arranged.
Among the present invention, described gel-type vehicle can also be the aqueous gel substrate that contains water solublity wetting agent, hydrophilic gel and PH regulator.The water solublity wetting agent can be selected from glycerol, propylene glycol, hyaluronic acid, heparin, aminoacid etc.Said hydrophilic gel can be selected from carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, silicone natural gum, alginic acid and sodium salt thereof etc.
Embodiment 2:
Different with embodiment 1 is: the consumption of interleukin-1 receptor antagonist protein is 10 mcg/ml.
Embodiment 3:
Different with embodiment 1 is: the consumption of interleukin-1 receptor antagonist protein is 100 mcg/ml.
Embodiment 4:
Different with embodiment 1 is: the consumption of interleukin-1 receptor antagonist protein is 500 mcg/ml.
Embodiment 5: contain the oil in water emulsion and the preparation thereof of interleukin-1 receptor antagonist protein
Use conventional mixing and emulsifying technology preparation to contain the emulsion composition of following ingredients
Polyethenoxy sorbitan monostearate, hydrogenated lanolin, Squalene, Cera Flava, silicone oil and vitamin E be heated to mix after 90 ℃ of fusions obtain the oil phase substrate raw material A.Pure water is heated to 95 ℃; Water raw material B is processed in glycerol, allantoin dissolving; With oil phase substrate raw material A, the biphase mixing emulsifying of water raw material B; Be cooled to 40 ℃, add phenoxyethanol, essence and the interleukin-1 receptor antagonist protein in the C phase raw material then and obtain the oil in water emulsion of interleukin-1 receptor antagonist protein with the further stirring and evenly mixing of agitator.Prepared emulsion has good stable property, and with contact skin after rapid breakdown of emulsion and impel the interleukin-1 receptor antagonist protein of aqueous phase to infiltrate skin as early as possible.This Emulsion also has good moisturizing function in addition.
Embodiment 6:
Different with embodiment 5 is: the consumption of interleukin-1 receptor antagonist protein is 500 mcg/ml.
Embodiment 7:
Different with embodiment 5 is: the consumption of interleukin-1 receptor antagonist protein is 10 mcg/ml.
Embodiment 8:
Different with embodiment 5 is: the consumption of interleukin-1 receptor antagonist protein is 10 microgram/grams.
Embodiment 9:
Different with embodiment 5 is: the consumption of interleukin-1 receptor antagonist protein is 20 microgram/grams.
Embodiment 10:
Different with embodiment 5 is: the consumption of interleukin-1 receptor antagonist protein is 500 microgram/grams.
Claims (9)
1. the application of interleukin-1 receptor antagonist protein in the preparation preparation for external application to skin.
2. the application of interleukin-1 receptor antagonist protein according to claim 1 in the preparation preparation for external application to skin; It is characterized in that; With gel-type vehicle, aqueous solution or the emulsion bases mix homogeneously of interleukin-1 receptor antagonist protein and external preparation for skin, process interleukin-1 receptor antagonist protein external preparation.
3. the application of interleukin-1 receptor antagonist protein according to claim 1 in the preparation preparation for external application to skin; It is characterized in that; After the interleukin-1 receptor antagonist protein is made into liposome earlier; Mix with gel-type vehicle, water or emulsion bases again, process interleukin-1 receptor antagonist protein external preparation.
4. the application of interleukin-1 receptor antagonist protein according to claim 1 in the preparation preparation for external application to skin; It is characterized in that; The interleukin-1 receptor antagonist protein is made into lyophilized powder earlier and preserves; Mix with the external-use gel that has prepared or aqueous solution or emulsion bases again before the use, process interleukin-1 receptor antagonist protein external preparation.
5. according to the application of the described interleukin-1 receptor antagonist protein of the arbitrary claim of claim 1 to 4 in the preparation preparation for external application to skin; It is characterized in that described interleukin-1 receptor antagonist protein is recombination human leukopenic-1 receptor antagonist protein or its modified protein.
6. the application of interleukin-1 receptor antagonist protein according to claim 5 in the preparation preparation for external application to skin; It is characterized in that the content of described interleukin-1 receptor antagonist protein in the external preparation is: 10 micrograms～500 mcg/ml (microgram/gram).
7. the application of interleukin-1 receptor antagonist protein according to claim 6 in the preparation preparation for external application to skin is characterized in that described gel-type vehicle is the aqueous gel substrate that contains water solublity wetting agent, hydrophilic gel and PH regulator.
8. the application of interleukin-1 receptor antagonist protein according to claim 7 in the preparation preparation for external application to skin; It is characterized in that described water solublity wetting agent is one or more the mixing in glycerol, propylene glycol, hyaluronic acid, heparin and the aminoacid.
9. the application of interleukin-1 receptor antagonist protein according to claim 7 in the preparation preparation for external application to skin; It is characterized in that described hydrophilic gel can be selected from one or more the mixing in carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, silicone natural gum, alginic acid and the sodium salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010254781.9A CN102370964B (en) | 2010-08-16 | 2010-08-16 | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010254781.9A CN102370964B (en) | 2010-08-16 | 2010-08-16 | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102370964A true CN102370964A (en) | 2012-03-14 |
| CN102370964B CN102370964B (en) | 2015-12-09 |
Family
ID=45790548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010254781.9A Active CN102370964B (en) | 2010-08-16 | 2010-08-16 | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102370964B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262625A (en) * | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | Use of lactoferin in treatment of allergen induced disorders |
-
2010
- 2010-08-16 CN CN201010254781.9A patent/CN102370964B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262625A (en) * | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | Use of lactoferin in treatment of allergen induced disorders |
Non-Patent Citations (1)
| Title |
|---|
| 陈代杰: "《微生物药物学》", 1 May 2008 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102370964B (en) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101667937B1 (en) | Cosmetics composition of peel-off type pack and method preparing the same | |
| WO2010143196A1 (en) | Novel synergistic transparent / translucent hydrogel composition; method of preparing it and a sheet / film made thereform | |
| Villegas et al. | Collagenase nanocapsules: An approach to fibrosis treatment | |
| CN105709267B (en) | A kind of human-like collagen cell migration gel | |
| KR20180005162A (en) | Cosmetic composition for skin whitening and method for producing the same | |
| EP1158021A1 (en) | Microgels and external preparations containing the same | |
| Deng et al. | Injectable in situ cross-linking hyaluronic acid/carboxymethyl cellulose based hydrogels for drug release | |
| CN107261197A (en) | One kind emulsification lipiodol vascular suppository material and its preparation method and application | |
| CN103992452A (en) | Star block copolymer with sugar, temperature and pH triple sensitivities, and preparing method thereof | |
| CN109431836A (en) | One kind removing scar composition and preparation method thereof | |
| CN103876947B (en) | A kind of sea cucumber peptide stabilization formulations and preparation method thereof and application | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| CN103211753B (en) | A kind of gel substrate | |
| US20140348873A1 (en) | Urea-Silicone Gel for Hyperkeratosis Treatment | |
| CN107753347A (en) | A kind of hydrogel sour pomegranate powder skin care item and preparation method thereof, application | |
| CN102370964A (en) | Application of interleukin receptor antagonist protein to preparation of external use skin preparation | |
| CN109077943B (en) | Preparation method and application of octacosanol-containing liposome | |
| CN101596310A (en) | A kind of artificial substrate membrane emulsifying paste that is used for wound repair | |
| CN110721162A (en) | Preparation method of nano-microspheres with biological activity | |
| CN100562306C (en) | Contain the biological beauty skin care item of body keratinized cell growth factor-2 and the preparation method of recombinant human keratinized cell growth factor-2 | |
| CN105199115B (en) | Preparation and application of injectable hydrogel with porous three-dimensional network structure | |
| CN106726672A (en) | A kind of cosmetic composition | |
| CN101518503A (en) | Novel cosmetic based on growth factor and serine | |
| CN103356700B (en) | Joint maintaining ointment | |
| CN106109279A (en) | A kind of Flos Rosae Rugosae collagen protein peptide facial mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230427 Address after: 620031 New Area of Meishan Economic Development Zone, Chengdu, Sichuan Province Patentee after: Sichuan peptide beauty Biotechnology Co.,Ltd. Address before: No. 2, 6th Floor, Unit 3, Building 2, No. 7 Yulin East Road, Wuhou District, Chengdu City, Sichuan Province, 610041 Patentee before: Li Xingde |